Chloroquine

Generic Name: Chloroquine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₆ClN_₃

CAS Number: 54-05-7

Unique Ingredient Identifier: 886U3H6UFF

Background: Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.

The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

Chloroquine was granted FDA Approval on 31 October 1949.

Indication: Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.

Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.

Associated Conditions: Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria

Associated Therapies: -

Clinical Trials

TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

Completed

Conditions: Malaria
Vivax Malaria
Falciparum Malaria
Malaria Recrudescence

Interventions: Drug: Arthemeter-lumefantrine
Drug: Chloroquine
Drug: Primaquine

First Posted Date: 2020-01-09

Last Posted Date: 2023-07-21

Lead Sponsor: Research Institute for Tropical Medicine, Philippines

Target Recruit Count: 159

Registration Number: NCT04222088

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Challenge
Drug: Chloroquine Phosphate
Drug: Pyrimethamine
Drug: Coartem
Drug: ibuprofen

First Posted Date: 2019-05-16

Last Posted Date: 2022-07-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 252

Registration Number: NCT03952650

Locations: 🇲🇱
Malaria Vaccine Center STTB/MRTC, Bamako, Mali

Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine

Conditions: Chloroquine Retinopathy
Proliferative Nephritis

Interventions: Drug: Chloroquine
Drug: Hydroxychloroquine

First Posted Date: 2018-09-27

Last Posted Date: 2018-09-27

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT03687905

Locations: 🇪🇬
Fatma Gheet, Tanta, Egypt

Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients

Phase 2

Active, not recruiting

Conditions: Vivax Malaria
G6PD Deficiency

Interventions: Drug: Chloroquine
Drug: Primaquine

First Posted Date: 2018-05-18

Last Posted Date: 2023-03-29

Lead Sponsor: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

Target Recruit Count: 106

Registration Number: NCT03529396

Locations: 🇧🇷
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil
🇧🇷
Centro de Pesquisa em Medicina Tropical (Cepem), Porto Velho, RO, Brazil

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: SARILUMAB
Drug: Azathioprine
Drug: Chloroquine
Drug: Hydroxychloroquine
Drug: Leflunomide
Drug: Methotrexate
Drug: Sulfasalazine

First Posted Date: 2018-02-28

Last Posted Date: 2022-04-28

Lead Sponsor: Sanofi

Target Recruit Count: 84

Registration Number: NCT03449758

Locations: 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷
Investigational Site Number 250006, Besancon, France
🇫🇷
Investigational Site Number 250016, Bordeaux, France

and more 30 locations